Mark Sumeray und Phase - Info zur Person

(1 - 21 von 24

)

Investegate |Amryt Pharma PLC Announcements | Amryt Pharma PLC:...

www.investegate.co.uk

Investegate announcements from Amryt Pharma PLC, POSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB

Aegerion begins Phase III study of lomitapide in Japan to treat HoFH...

www.clinicaltrialsarena.com

Aegerion chief medical officer Mark Sumeray said the pivotal trial marks an important milestone for the company and Japanese HoFH patients.

AZP-3601's Efficacy Data Support Phase 3 Trial Next Year ...

hypoparathyroidismnews.com

— ... safety and efficacy data from Cohort [group] 2 validate the findings from the first cohort of patients in this study,” Mark Sumeray, MD, ... › ...

shardadmin, Author at Shard Capital Stockbrokers - Page www.shardcapitalstockbrokers.com › ...

www.shardcapitalstockbrokers.com

Mark Sumeray, Chief Medical Officer of Amryt, commented: “We are delighted to have initiated the first site participating in our Phase 3 clinical ...

Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa ...link.springer.com › article

link.springer.com

... difficulties of designing an appropriate study in the complex setting of ... Results from EASE will be published and summary data will be made available on EudraCT and ClinicalTrials.gov Dr. Mark Sumeray, BS MS MD FRCS ... Qualified Person for Pharmacovigilance, FGK Pharmacovigilance GmbH.

- Document - Oleogel-S10 Phase 3 study "EASE" for Galego.gale.com › i.do

go.gale.com

Author(s): Johannes S. Kern, Agnes Schwieger-Briel, Sandra Lowe, Mark Sumeray, Charles Davis, and Anna E. Martinez . Source: Trials. Document Type: ...

Amryt Pharma #AMYT & Falanx Group #FLX - Audioboom

audioboom.com

— Mark Sumeray, Chief Medical Officer of Amryt Pharma #AMYT discusses the commencement of "EASE", its Phase 3 clinical trial of AP101, ... › posts › 5...

Amolyt Pharma to Present Full Phase 2a Data MarketWatch

www.marketwatch.com

— At the International HypoPARAthyroidism Conference, Amolyt Pharma's Chief Medical Officer Mark Sumeray, M.D., will discuss the ... › pr...

Amryt Pharma: Positive Results from Phase III Trial - Five ...www.fmp-tv.co.uk › › amryt-pharma-posit...

www.fmp-tv.co.uk

Dr Mark Sumeray, Chief Medical Officer of Amryt commented: “It is very ... on the speed of wound healing in such a complex clinical situation.

Amryt to begin Phase 3 trial of drug to treat rare disorder

www.researchandinnovation.ie

— Mark Sumeray, Chief Medical Officer of Amryt, said: “We are delighted to have initiated the first site participating in our Phase 3 clinical ... › ...